Champions Oncology Inc

Champions Oncology maintains a liquidity position of $9.79 million in cash and equivalents, representing 30.3% of total assets, while total liabilities of $28.57 million are significantly higher than equity of $3.77 million. The company's price-to-book ratio of 22.86 indicates a premium valuation relative to its tangible net worth. With a current ratio of 0.94, the firm faces short-term liquidity constraints, as current liabilities exceed current assets. Profitability metrics show a net income of $4.70 million on $56.94 million in revenue, yielding a 8.26% net margin. Return on equity of 1.25% and return on assets of 0.15% indicate weak capital efficiency relative to industry benchmarks. The company's operating margin of 8.04% (calculated from $4.55 million operating income) lags behind the median for Life Sciences Tools & Services firms. Geographically, Champions Oncology's revenue is concentrated in North America, with no material disclosures of international operations. Segment-wise, the company operates as a single business unit focused on oncology research services, with no material diversification across product lines or therapeutic areas. The company's revenue growth trajectory shows a 0.0% year-over-year change in the most recent fiscal year, with no disclosed guidance for the next fiscal year. Free cash flow of $5.95 million reflects a 104.3% conversion rate from operating cash flow, but capital expenditures of -$389,000 suggest asset disposals or non-cash adjustments. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The debt-to-equity ratio of 0.06 suggests minimal leverage, but the low equity base of $3.77 million relative to total liabilities of $28.57 million creates structural fragility. No dilution sources were identified in recent filings. Recent 10-K filings disclose ongoing research collaborations with pharmaceutical companies but no material litigation or regulatory actions. The ESG controversies score of 100.00 indicates no recent controversies, while governance and social scores of 43.99 and 29.34 respectively suggest room for improvement in ESG practices.